| 1 | 10057 | LAO-MA036 | ETCTN | Female Reproductive System Cancer;Lymphoma;Skin Cancer | Temporarily Closed to Accrual | A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors | II | 55/68 | N/A | INTERVENTION |
| 2 | 10075 | LAO-CA043 | ETCTN | Leukemia | Active | A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia | I | 30/48 | N/A | INTERVENTION |
| 3 | 10170 | LAO-CT018 | ETCTN | Kidney Cancer;Solid Tumor | Active | A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies | II | 18/60 | N/A | INTERVENTION |
| 4 | 10218 | LAO-MA036 | ETCTN | CNS Cancer (Primary tumor) | Active | A Phase 1b Trial of Telaglenastat (CB-839) HCl in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma | I | 21/40 | N/A | INTERVENTION |
| 5 | 10219 | LAO-MA036 | ETCTN | Myeloma | Active | Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | I | 21/36 | N/A | INTERVENTION |
| 6 | 10300 | LAO-CT018 | ETCTN | Leukemia | Temporarily Closed to Accrual | BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1 (BLAST MRD AML-1): A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia | II | 11/124 | N/A | INTERVENTION |
| 7 | 10301 | LAO-CT018 | ETCTN | Male Reproductive System Cancer | Active | A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | I/II | 9/24 | N/A | INTERVENTION |
| 8 | 10334 | LAO-CT018 | ETCTN | Leukemia | Temporarily Closed to Accrual | BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy | II | 12/76 | N/A | INTERVENTION |
| 9 | 10387 | EDDO-NY313 | ETCTN | AIDS-related Malignancy and Condition;Solid Tumor | Active | Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection | I | 1/18 | N/A | INTERVENTION |
| 10 | 10406 | LAO-PA015 | ETCTN | Gastrointestinal Cancer | Active | Phase I/Ib Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers | I | 3/90 | N/A | INTERVENTION |
| 11 | 10410 | LAO-11030 | ETCTN | Gastrointestinal Cancer | Temporarily Closed to Accrual | A Phase 1 Study of IPdR in Combination with Capecitabine and Radiotherapy in Rectal Cancer | I | 1/30 | N/A | INTERVENTION |
| 12 | 9892 | LAO-PA015 | ETCTN | AIDS-related Malignancy and Condition;Female Reproductive System Cancer | Active | Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer | I | 9/76 | N/A | INTERVENTION |
| 13 | 9938 | LAO-PA015 | ETCTN | Solid Tumor | Active | Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors | I | 51/66 | N/A | INTERVENTION |
| 14 | A021806 | ALLIANCE | NCTN | Gastrointestinal Cancer | Active | A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | III | 73/352 | N/A | INTERVENTION |
| 15 | A041501 | ALLIANCE | NCTN | Leukemia | Active | A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL | III | 233/341 | N/A | INTERVENTION |
| 16 | A041703 | ALLIANCE | NCTN | Leukemia | Active | A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease | II | 45/64 | N/A | INTERVENTION |
| 17 | A051902 | ALLIANCE | NCTN | Lymphoma | Active | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas | II | 2/182 | N/A | INTERVENTION |
| 18 | A071401 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Active | Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations | II | 40/124 | 328 | SCREENING, INTERVENTION |
| 19 | A171901 | ALLIANCE | NCORP | Lung, Mediastinal, and Pleural Cancer | Active | Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice) | II | 33/100 | N/A | INTERVENTION |
| 20 | A221702 | ALLIANCE | NCORP | Breast Cancer | Active | ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence after Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection with and without Axillary Reverse Mapping | III | 380/516 | N/A | INTERVENTION |
| 21 | AREN1721 | COG | NCTN | Kidney Cancer | Temporarily Closed to Accrual | A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups | II | 11/40 | N/A | INTERVENTION |
| 22 | DCP-001 | DCP | NCORP | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor | Active | Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) | Other | N/A | N/A | OTHER |
| 23 | EA1181 | ECOG-ACRIN | NCTN | Breast Cancer | Active | EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer) | II | 885/1250 | N/A | INTERVENTION |
| 24 | EA5163 | ECOG-ACRIN | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-Driven Analysis | III | 371/846 | N/A | INTERVENTION |
| 25 | EA6141 | ECOG-ACRIN | NCTN | Skin Cancer | Active | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | II/III | 303/600 | N/A | INTERVENTION |
| 26 | EA8134 | ECOG-ACRIN | NCTN | Male Reproductive System Cancer | Active | InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | III | 49/200 | N/A | INTERVENTION |
| 27 | EAA173 | ECOG-ACRIN | NCTN | Myeloma | Active | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | III | 91/288 | N/A | INTERVENTION |
| 28 | NCICOVID | NCI | NCI | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor | Active | NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study | Other | N/A | 1592 | SCREENING, OTHER |
| 29 | NRG-BR005 | NRG | NCTN | Breast Cancer | Temporarily Closed to Accrual | A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery | II | 105/175 | N/A | INTERVENTION |
| 30 | NRG-GY020 | NRG | NCTN | Female Reproductive System Cancer | Active | A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer | III | 98/168 | N/A | INTERVENTION |
| 31 | NRG-GY022 | NRG | NCTN | Solid Tumor | Active | Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin | I | 203/250 | N/A | INTERVENTION |
| 32 | PBTC-051 | PBTC | MISCELLANEOUS | CNS Cancer (Primary tumor) | Active | Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects with Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma | I | 25/45 | N/A | INTERVENTION |
| 33 | S0820 | SWOG | NCORP | Gastrointestinal Cancer | Active | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) | III | 326/491 | N/A | INTERVENTION |
| 34 | S1501 | SWOG | NCORP | Breast Cancer | Active | Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III | III | 259/817 | 276 | SCREENING, INTERVENTION |
| 35 | S1712 | SWOG | NCTN | Leukemia | Active | A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease | II | 62/84 | N/A | INTERVENTION |
| 36 | S1914 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC | III | 65/480 | N/A | INTERVENTION |
| 37 | S1933 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status | II | 17/47 | N/A | INTERVENTION |
| 38 | S1937 | SWOG | NCTN | Urothelial/ Bladder Cancer | Active | A Phase III Randomized Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy | III | 3/465 | N/A | INTERVENTION |
| 39 | S2012 | SWOG | NCTN | Endocrine Cancer | Active | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) | II/III | 0/189 | N/A | INTERVENTION |
| 40 | S2013 | SWOG | NCORP | N/A | Active | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | Other | N/A | N/A | OTHER |
| 41 | 10026 | LAO-MA036 | ETCTN | Leukemia | Active | A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia | I | 54/48 | N/A | INTERVENTION |
| 42 | 10058 | LAO-TX035 | ETCTN | Gastrointestinal Cancer | Active | A Phase I Study of Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum | I | 3/21 | N/A | INTERVENTION |
| 43 | 10076 | LAO-TX035 | ETCTN | Myeloma | Active | A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma | I | 13/40 | N/A | INTERVENTION |
| 44 | 10150 | LAO-11030 | ETCTN | Female Reproductive System Cancer | Active | A Randomized Phase 2 Study of Bevacizumab and Either Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant or Platinum Refractory Ovarian Cancer | I/II | 61/96 | N/A | INTERVENTION |
| 45 | 10181 | LAO-NC010 | ETCTN | Gastrointestinal Cancer | Active | A Phase 2 Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer | II | 5/15 | 70 | SCREENING, INTERVENTION |
| 46 | 10184 | LAO-NCI | ETCTN | Head and Neck Cancer | Active | Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) | I | 3/34 | N/A | INTERVENTION |
| 47 | 10208 | LAO-11030 | ETCTN | Gastrointestinal Cancer | Active | A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma | I/II | 33/64 | 337 | SCREENING, INTERVENTION |
| 48 | 10221 | LAO-TX035 | ETCTN | Solid Tumor | Active | A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors | I/II | 34/102 | N/A | INTERVENTION |
| 49 | 10268 | LAO-NCI | ETCTN | Endocrine Cancer;Lung, Mediastinal, and Pleural Cancer | Active | Randomized Phase II Trial of Topotecan Plus M6620 (VX-970, Berzosertib) Vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer | II | 80/98 | N/A | INTERVENTION |
| 50 | 10272 | NCICCR | MISCELLANEOUS | Male Reproductive System Cancer | Active | A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer | II | 136/200 | N/A | INTERVENTION |